Ergothioneine and Drug-Induced Liver Injury

Ergothioneine & Liver Health

8 liver injury markers reduced

In a 2025 CCl4 mouse model, ergothioneine at 5-10 mg/kg/day for six weeks reduced three liver function markers (ALT, AST, total bilirubin) and five fibrosis markers (laminin, hydroxyproline, alpha-SMA, collagen I and III) simultaneously.

Mao et al., J Appl Toxicol, 2025

Thiol antioxidant

proposed glutathione-sparing chemistry

Nrf2 pathway

implicated in animal models

No human trial

all DILI evidence is preclinical

Mao et al., J Appl Toxicol, 2025

View as image ↗

Drug-induced liver injury (DILI) is among the leading reasons approved drugs are restricted or withdrawn after reaching the market, and it accounts for a substantial share of acute liver failure cases in developed countries. The challenge with DILI is that it strikes through several different mechanisms depending on the drug, and no single pharmacological antidote covers all of them. What most forms of DILI share, though, is oxidative stress: drugs or their metabolites overwhelm the liver's antioxidant capacity, deplete glutathione, and trigger a cascade of cell death and inflammation. That shared mechanism is where ergothioneine becomes relevant.

Ergothioneine is a sulfur-containing amino acid produced almost exclusively by fungi and acquired by humans through dietary mushroom consumption. It carries a thiol group, the same type of reactive sulfur bond that makes glutathione and N-acetyl cysteine (NAC) effective antioxidants. It accumulates in tissues under oxidative stress, and a damaged liver actively imports more of it by upregulating its dedicated transporter.^[8] And it has been linked to activation of the Nrf2 pathway, the master regulator of cellular antioxidant gene expression. For a broader introduction to ergothioneine's biology, see What Is Ergothioneine?. For its hepatoprotective effects across liver disease more broadly, see Ergothioneine and Liver Health: Hepatoprotective Research.

What Drug-Induced Liver Injury Actually Is

DILI is not a single disease. It is a category that includes dozens of different injury patterns caused by hundreds of different drugs and supplements, through multiple distinct mechanisms. Idiosyncratic reactions (unpredictable injury in a small fraction of patients) account for most drug withdrawals and liver failure cases. Dose-dependent toxicity, where the drug reliably causes liver damage above a threshold dose, is the other major pattern. Acetaminophen (covered separately in Ergothioneine and Acetaminophen Liver Injury) is the most clinically significant dose-dependent example.

What most DILI mechanisms share is involvement of reactive metabolites and oxidative stress. The liver metabolizes drugs through cytochrome P450 enzymes, generating reactive oxygen species and sometimes highly reactive drug metabolites as byproducts. When these exceed the liver's antioxidant clearance capacity, oxidative damage accumulates. Glutathione is the first line of defense; when it is depleted, lipid peroxidation propagates, mitochondria are impaired, and hepatocyte death follows.

A second shared feature relevant to ergothioneine: many DILI-causing drugs specifically deplete glutathione. Drugs like acetaminophen, antiepileptics, and some antibiotics create reactive metabolites that conjugate with glutathione directly, exhausting the supply. Others induce cytochrome P450 enzymes in ways that generate excess reactive oxygen species. In both cases, the result is a liver operating with degraded antioxidant capacity, trying to process ongoing metabolic loads with damaged defenses.

An antioxidant that can work even when glutathione is depleted, or better yet prevent glutathione depletion in the first place, would address the core vulnerability. That is ergothioneine's proposed mechanistic position — a rationale for testing it, not a finding in its own right.

The 1983 Kawano Studies: The Historical Foundation

The oldest reference connecting ergothioneine to hepatic drug processing is a two-part series by Kawano and colleagues, published in Chemical and Pharmaceutical Bulletin in 1983. The first paper is titled "Effects of ergothioneine on the hepatic drug metabolizing enzyme system and on experimental hepatic injury in rats."^[1] The second is titled "Inhibitory effect on lipid peroxide formation in mouse liver."^[2]

An important caveat belongs here, because these two papers are cited repeatedly across the ergothioneine literature: neither has an abstract indexed in PubMed. Their titles establish what the researchers set out to measure — the drug-metabolizing enzyme system, experimental liver injury, and lipid peroxide formation — but the direction and magnitude of the reported effects cannot be verified from the indexed record. Secondary sources frequently describe these papers as showing protection. That description may well be correct, but it is not something a reader can confirm without retrieving the 1983 print originals, and this article will not assert it as established.

What the titles do establish is that the question of ergothioneine's interaction with hepatic drug metabolism was posed more than forty years ago. That matters, because the drug-metabolizing enzyme system is precisely where DILI begins. Cytochrome P450 enzyme activity determines how much reactive intermediate a drug generates; a compound acting at that step would be operating upstream of oxidative damage rather than merely mopping up after it. Lipid peroxidation, the subject of the second paper, is the downstream chain reaction that spreads membrane damage beyond the initial injury site. Together the two titles sketch a hypothesis spanning both ends of the injury cascade — a hypothesis that modern work has since taken up with better methods and fuller reporting.

Mao 2025: The Most Recent Preclinical Data

Carbon tetrachloride (CCl4) hepatotoxicity is a well-established chemical DILI model, used in liver research for decades precisely because it reliably produces oxidative liver injury and, with repeated dosing, fibrosis, the long-term scarring consequence of chronic liver damage. It is a direct chemical hepatotoxin, not a drug metabolite, but its mechanism (reactive radical generation, glutathione depletion, oxidative hepatocyte death) mirrors the core DILI pathway closely enough that results in this model are considered DILI-relevant.

Mao and colleagues published a 2025 study using this model to test ergothioneine.^[3] Mice received ergothioneine at 5 or 10 mg/kg per day for six weeks alongside CCl4 administration. The results covered both acute liver function and fibrosis markers. Ergothioneine reduced ALT (a marker of hepatocyte death), AST (another liver injury enzyme), and total bilirubin. On the fibrosis side, it reduced alpha-smooth muscle actin (a marker of activated stellate cells, which drive scar tissue formation), collagen I and III, laminin, and hydroxyproline.

The mechanistic analysis combined metabolomics and network pharmacology to propose a molecular target. The authors' model is that ergothioneine inhibits glycerophospholipid metabolism through an enzyme called PLA2G2A, which in turn suppresses activation of the TGF-beta/Smads signaling pathway. TGF-beta is the primary driver of hepatic fibrosis, and the study did confirm that ergothioneine significantly inhibited both hepatic inflammation and TGF-beta/Smads signaling. If the PLA2G2A step holds up under direct testing, it would offer a single upstream explanation for why ergothioneine moved the acute injury markers and the fibrosis endpoints together rather than one or the other.

This is the most detailed molecular target analysis of ergothioneine's hepatoprotective mechanism currently available, and it is relevant to DILI because CCl4 injury is a standard chemical hepatotoxicity model. Two limits are worth stating plainly: the authors identify PLA2G2A as a potential target inferred from combined metabolomics and network pharmacology rather than confirmed by direct genetic knockout, and the model is chemical hepatotoxicity in mice, not drug-induced injury in people.

Mao et al. (2025) · Journal of Applied Toxicology

Population

Mice given intraperitoneal 40% CCl4 (2 mL/kg, twice weekly) for six weeks to induce liver fibrosis

Intervention

Ergothioneine 5 or 10 mg/kg/day by intragastric administration for six weeks

Comparator

CCl4-treated control mice without ergothioneine

Finding

Ergothioneine reduced serum ALT, AST, and total bilirubin, and lowered laminin, hydroxyproline, alpha-SMA, collagen I and collagen III. It suppressed hepatic inflammation and the TGF-beta/Smads pathway. Integrated metabolomics and network pharmacology pointed to PLA2G2A as a likely target.

positive Consistent, multi-marker benefit — but in a mouse chemical-toxin model, with the molecular target inferred computationally rather than confirmed by knockout.

Mao et al., Journal of Applied Toxicology, 2025 (PMID 39579000)

Ischemia-Reperfusion as an Acute Hepatotoxic Injury Model

Bedirli and colleagues tested ergothioneine pretreatment in a rat hepatic ischemia-reperfusion model in 2004.^[4] This model creates acute, intense oxidative liver injury by cutting and then restoring blood flow to the liver; the sudden restoration of oxygenated blood generates a burst of reactive oxygen species that can kill hepatocytes rapidly. The mechanism shares the oxidative burst and glutathione depletion features of acute DILI.

Wistar rats received L-ergothioneine at 1.2 mg/kg/day by gavage for three weeks before the injury. Compared with untreated controls, the ergothioneine group showed significantly lower serum AST, ALT and LDH at every reperfusion time point measured, and significantly lower tissue malondialdehyde, a lipid peroxidation marker, at 30 and 60 minutes. Reperfusion itself induced HSP70, and ergothioneine-pretreated animals showed significantly higher HSP70 levels still — the effect the authors highlight in the paper's title as the route of protection. HSP70 is a heat shock protein that helps cells survive acute stress by preventing protein misfolding and aggregation, which is a different kind of defense from direct radical scavenging: it prepares cells to withstand an insult rather than neutralizing the insult itself.

That distinction is what makes the result interesting for DILI, though the connection is an inference rather than something this study tested. Many hepatotoxic drugs generate protein adducts — reactive metabolites that bind liver proteins and deform them — in addition to causing oxidative damage. A chaperone response would in principle address that second kind of damage, which antioxidants do not. Whether it does so against drug-derived adducts specifically has not been examined.

Nrf2: The Mechanism That Would Matter Most

The 2022 review by Fu and Shen in Frontiers in Pharmacology surveyed ergothioneine as a natural antioxidant across a range of oxidative-stress-related diseases — diabetes, ischemia-reperfusion-related conditions including cardiovascular and liver disease, neurodegenerative disease, and others — and summarized the proposed action mechanisms behind each.^[5] Liver disease is one category within that broader survey rather than its main subject, and the review is a narrative synthesis, not a systematic one. It is useful here for situating ergothioneine among antioxidants, not as independent evidence of a liver-specific effect.

Nrf2 (nuclear factor erythroid 2-related factor 2) is a transcription factor that functions as the cell's master switch for antioxidant gene expression. Under normal conditions it is kept inactive. Under oxidative stress, it is released, enters the nucleus, and activates the antioxidant response element (ARE), which drives expression of protective genes: glutamate-cysteine ligase (makes glutathione), superoxide dismutase, catalase, heme oxygenase-1, and others.

If ergothioneine engages this pathway, it would do something a simple radical scavenger cannot: rather than only neutralizing a reactive species, it would help restore the cell's capacity to manufacture its own protective molecules. That distinction matters in DILI specifically, because the injury characteristically depletes those very molecules.

It is worth being precise about what supports this, because Nrf2 is often asserted more confidently than the liver-specific evidence warrants. The clearest in-vivo result comes from Dare and colleagues, who treated diabetic rats with liver injury using L-ergothioneine (35 mg/kg) with or without metformin for seven weeks.^[10] Ergothioneine reduced liver hypertrophy, liver injury, triglycerides, oxidative stress and inflammation, and normalized hepatic mRNA expression of nuclear factor erythroid 2-related factor 2 alongside NF-kappaB, TGF-beta1, SREBP-1c and sirtuin-1. That is a direct measurement of Nrf2-related transcription in injured liver tissue rather than an inference from cell work.

Two caveats attach to it. The model is diabetic liver complication, not drug-induced injury. And normalizing mRNA expression across a panel of transcription factors demonstrates that ergothioneine shifts the pathway, not that Nrf2 is the step through which the benefit is delivered — no knockout or inhibitor test was run to establish that. Notably, Mao 2025, the most detailed liver mechanism study available, did not implicate Nrf2 at all; its route ran through PLA2G2A and TGF-beta/Smads. The honest summary is that ergothioneine engages Nrf2 in liver tissue, and that the pathway is one of several it touches rather than a settled single explanation.

Two reviews are frequently cited alongside this mechanism, and both deserve accurate characterization. Cheah and Halliwell's 2021 "Ergothioneine, recent developments" is a brief overview noting that ergothioneine accumulates at high levels in the body from diet, that blood levels decline with age and disease onset, and that it may play physiological roles in health and disease.^[6] It is a survey of the field rather than a liver-specific mechanistic argument.

Lam-Sidun and colleagues' 2021 review in the International Journal of Molecular Sciences examined preclinical evidence for ergothioneine in cardiometabolic health.^[7] Its framing is notably cautious: the authors state that the in vivo effects of ergothioneine and its underlying therapeutic mechanisms in the whole organism "are not as clear" as the cellular data suggest, and that there are no well-defined clinical prevention or intervention trials of the compound in chronic disease. That is a review counselling restraint about the strength of the evidence, and it should be read that way.

The Liver's Own Verdict: It Imports More When Damaged

One of the more persuasive pieces of evidence is not an intervention study at all. Cheah and colleagues examined ergothioneine in the livers of a guinea pig model of non-alcoholic fatty liver disease and found that ergothioneine levels in the damaged liver were elevated, and that the elevation correlated with cholesterol accumulation and disease severity.^[8]

The mechanism behind the accumulation is the informative part. The researchers identified increased expression of RUNX1, a transcription factor that upregulates OCTN1, the transporter dedicated specifically to ergothioneine uptake. In other words, the injured liver was not passively accumulating a compound floating past it. It was actively building more of the machinery required to pull ergothioneine in, and it did so in proportion to how sick it was. The same livers also showed increased HSP70, mirroring the protein response Bedirli's team observed, and showed no significant rise in two oxidative damage markers, F2-isoprostanes and protein carbonyls.

The authors' interpretation is appropriately measured: the accumulation may represent a stress response by the damaged liver to suppress oxidative damage and delay tissue injury, potentially through direct antioxidant action, HSP70 induction, or iron chelation. They also add a caution aimed at other researchers — that similar accumulation may occur in other disease models and should be accounted for.

This is not a DILI study, and fatty liver disease is not drug-induced injury. But it addresses a question that intervention studies cannot: does the liver itself behave as though ergothioneine is worth having when it is under oxidative stress? The transporter data says it does.

Taken together, the DILI-relevant evidence consists of two 1983 papers whose results cannot be verified from the indexed record, a rat ischemia-reperfusion model, a mouse chemical-toxin model, a diabetic rat liver-injury model with gene-expression data, and an observation about transporter behavior in a guinea pig fatty liver model. These point in a consistent direction, and no study identified here contradicts the hepatoprotective signal. That consistency is genuine and worth noting — but it is consistency across four species, four different kinds of injury, and not one instance of a hepatotoxic drug given to a human being.

What Would Make This Evidence Clinically Meaningful

The honest picture: all direct evidence for ergothioneine in DILI contexts is preclinical. No human trial has tested ergothioneine in patients with DILI, whether idiosyncratic or dose-dependent.

The closest human data is Cheah and colleagues' 2017 study, the first to give pure ergothioneine to healthy human volunteers (discussed in Liver Ergothioneine Levels and Disease Risk).^[9] It established that orally administered ergothioneine is avidly absorbed and retained, with less than 4% excreted in urine. On oxidative damage and inflammation biomarkers — allantoin, 8-hydroxy-2'-deoxyguanosine, 8-iso-PGF2alpha, protein carbonylation, and C-reactive protein — the study saw decreasing trends, but the authors are explicit that most of the changes were non-significant.

That result is easy to over-read in either direction. It is not evidence that ergothioneine does nothing; the authors' own reading is that it may act as a major antioxidant primarily under conditions of oxidative stress, and these were healthy volunteers with no such stress to counteract. Nor is it evidence of benefit. It is a pharmacokinetic study establishing that the compound reaches the body and stays there, which is the prerequisite for testing it in a population that actually has liver injury — not a substitute for that test.

What a meaningful study would require: a controlled design in either a drug-challenged animal model with a specific hepatotoxin (acetaminophen, isoniazid, or another well-characterized DILI agent), with pharmacokinetic data confirming ergothioneine tissue concentrations, and liver histology alongside function markers. Or a human pilot study in a population at known DILI risk (for example, patients on hepatotoxic antibiotics or antiepileptics) measuring liver enzyme trajectories with and without ergothioneine supplementation.

These studies do not yet exist. The mechanism is coherent and has support in adjacent animal models. The evidence gap is not a contradiction; it is an absence of experimental attention to this specific question — and until that attention arrives, the appropriate description of ergothioneine's role in DILI is "biologically plausible and untested in humans," not "protective."

1. Cell and tissue studiescompleted

   Ergothioneine's thiol chemistry, its uptake through the dedicated OCTN1 transporter, and its antioxidant behavior are well characterized at the cellular and tissue level.

2. Animal models of liver injurycurrent

   This is where the evidence sits. CCl4 chemical hepatotoxicity in mice (Mao 2025), ischemia-reperfusion in rats (Bedirli 2004), diabetic liver injury with Nrf2 measurement in rats (Dare 2021), fatty liver transporter response in guinea pigs (Cheah 2016), and two 1983 rodent papers whose results are not verifiable from the indexed record. None of these administered a hepatotoxic drug.

3. Human case reports in DILImissing

   No published case reports of ergothioneine used in a person with drug-induced liver injury.

4. Small human trial in an at-risk populationmissing

   Never conducted. The only human dosing study (Cheah 2017) enrolled healthy volunteers, measured oxidative damage biomarkers rather than drug-challenge outcomes, and found most changes non-significant.

5. Large randomized controlled trialmissing

   Not conducted, and not currently registered for a DILI indication.

6. Meta-analysis of human DILI outcomesmissing

   Impossible without human trials to pool.

Every direct result for ergothioneine in a liver injury context comes from animals or cells. The human rungs of this ladder are entirely empty — there is not a single case report, let alone a trial, of ergothioneine given to a person with drug-induced liver injury. A coherent mechanism supported by consistent animal data is a reason to run those trials, not a reason to act as though they have already reported.

Kawano 1983 [1][2]; Mao 2025 [3]; Bedirli 2004 [4]; Cheah 2016 [8]; Cheah 2017 [9]; Dare 2021 [10]

Mechanism Map

Where Ergothioneine Is Proposed to Act — and How Much Is Actually Known at Each Step

Drug-induced liver injury is a sequence, not a single event. Ergothioneine has a proposed action at every stage of that sequence, which is what makes the mechanistic story compelling. But the evidence behind each step is not equal. Read the right-hand column with the evidence chip attached to it — the earliest and most interesting claim is also the least verifiable.

Animal / cell resultInferred, not shownNot verifiable

1. 1

   Injury stage

   Drug metabolism by cytochrome P450

   The liver processes a drug and generates reactive metabolites as a byproduct. Everything downstream starts here.

   Ergothioneine

   Not verifiable

   Proposed modulation of the hepatic drug-metabolizing enzyme system, which would reduce reactive metabolite production before any damage begins.

   Kawano 1983 [1] — title only, no indexed abstract

2. 2

   Injury stage

   Glutathione depletion

   Reactive metabolites conjugate with glutathione and exhaust the supply, leaving the liver without its primary defense.

   Ergothioneine

   Inferred, not shown

   Two proposed routes. Sparing: scavenging reactive species with its own thiol group so glutathione is not consumed — chemically reasonable, widely repeated, never directly demonstrated in a DILI model. Restocking: engaging Nrf2, which drives glutathione synthesis. Ergothioneine normalized hepatic Nrf2 expression in injured diabetic rat liver, though not in a drug-injury model.

   Sparing: rationale only. Nrf2: Dare 2021 [10]

3. 3

   Injury stage

   ROS accumulation and lipid peroxidation

   Unquenched radicals start a chain reaction through cell membranes, spreading damage past the original site.

   Ergothioneine

   Animal / cell result

   Bedirli 2004 measured reduced tissue malondialdehyde, a lipid peroxidation marker, in ergothioneine-pretreated rat liver. A 1983 paper reports inhibition of lipid peroxide formation in mouse liver but has no indexed abstract.

   Bedirli 2004 [4]; Kawano 1983 [2] unverified

4. 4

   Injury stage

   Protein adducts and proteostasis failure

   Reactive metabolites bind and deform liver proteins. Antioxidants alone do not address this.

   Ergothioneine

   Animal / cell result

   HSP70 induction, a chaperone response that helps cells survive misfolding rather than neutralizing the toxin. Raised in ergothioneine-pretreated rat liver, and also elevated alongside ergothioneine in the fatty liver model.

   Bedirli 2004 [4]; Cheah 2016 [8]

5. 5

   Injury stage

   Hepatocyte death

   Cells rupture and release their enzymes into blood — the ALT and AST rise that flags injury clinically.

   Ergothioneine

   Animal / cell result

   Reduced ALT, AST and total bilirubin in CCl4-treated mice, and reduced AST, ALT and LDH across all reperfusion time points in rats.

   Mao 2025 [3]; Bedirli 2004 [4]

6. 6

   Injury stage

   Stellate cell activation and fibrosis

   With repeated injury, scar tissue replaces working liver. This is the long-term consequence.

   Ergothioneine

   Animal / cell result

   Reduced alpha-SMA, collagen I and III, laminin and hydroxyproline, with suppression of the TGF-beta/Smads cascade. PLA2G2A identified as a likely target by combined metabolomics and network pharmacology, not by knockout.

   Mao 2025 [3]

Running alongside all six stages

The damaged liver imports more ergothioneine as it gets sicker

In a guinea pig fatty liver model, ergothioneine levels rose in proportion to disease severity, driven by increased RUNX1 expression upregulating OCTN1, the transporter specific to ergothioneine. This is the one line of evidence that does not depend on a researcher choosing to administer the compound — though it comes from fatty liver disease, not drug-induced injury. Cheah 2016 [8]

How to read it: a mechanism that covers every stage of an injury cascade looks stronger than one that covers a single step, and that breadth is the real argument for studying ergothioneine in DILI. But breadth is not depth. Four of these six steps rest on two rodent studies, one step rests on chemical reasoning alone, and the first step — the one that would matter most, because it acts before damage starts — rests on a 1983 paper whose results cannot be checked against the indexed record. Every entry on this map comes from animals or cells. None involves a person with drug-induced liver injury. Nothing here is medical advice.

Sources: Kawano 1983 [1][2]; Mao 2025 [3]; Bedirli 2004 [4]; Cheah 2016 [8]; Dare 2021 [10]. Cascade stages are a simplified composite of common DILI pathways and are not drawn to any quantitative scale.

When to seek care

Critical

Suspected drug-induced liver injury is a medical emergency, not a supplement question

Concern

Drug-induced liver injury can progress to acute liver failure. Warning signs include yellowing of the skin or eyes, dark urine, pale stools, persistent nausea or vomiting, right-upper-abdominal pain, unusual fatigue, and confusion. Delaying care to try a supplement first can be fatal, and acetaminophen overdose in particular has a narrow treatment window during which the established antidote works best.

What the research says

If you suspect a medication is harming your liver, contact a clinician or emergency service immediately. Do not stop a prescribed medication on your own without medical advice, and do not substitute any mushroom-derived compound for evaluation or for an established treatment such as N-acetyl cysteine.

Particularly relevant for: Anyone taking a medication associated with liver injury, anyone with existing liver disease, and anyone experiencing the symptoms above

What to do

Seek medical evaluation for suspected liver injury rather than self-treating. Tell your clinician about every supplement you take, including mushroom products, because supplements are themselves a recognized cause of liver injury.

General clinical safety guidance. No ergothioneine product is approved to prevent or treat drug-induced liver injury, and no human trial supports such use. This article is educational and is not medical advice.

Ergothioneine enters the body almost exclusively through mushrooms in the diet. For the dietary context, Why Only Fungi Make Ergothioneine explains why no plant foods contain meaningful amounts and which mushroom species have the highest concentrations. For the inflammatory component of DILI, where ergothioneine has been reported to suppress inflammatory cytokines in animal models, the broader anti-inflammatory picture is covered in Ergothioneine and Inflammation: Anti-Inflammatory Research.

The Bottom Line

Ergothioneine has shown hepatoprotective effects in DILI-relevant preclinical contexts: the 2004 Bedirli ischemia-reperfusion model in rats and the 2025 Mao CCl4 model in mice, where it reduced three liver function markers and five fibrosis markers via the PLA2G2A and TGF-beta/Smads pathways. A 2016 study adds a different kind of evidence — a damaged liver upregulates OCTN1 and imports more ergothioneine as disease severity rises. Two frequently cited 1983 Kawano papers have no abstracts indexed in PubMed, so their reported effects cannot be verified from the public record. The proposed mechanism spans direct antioxidant action and gene-level defense activation: Dare 2021 found ergothioneine normalized hepatic Nrf2 expression in injured rat liver, and Bedirli 2004 attributed its protection to HSP70 induction. Notably, the most detailed liver mechanism study (Mao 2025) did not implicate Nrf2, so the pathway picture is plural rather than settled. No human DILI trial exists, and the only human dosing study was in healthy volunteers with mostly non-significant biomarker changes. The mechanistic case is coherent; the clinical case has not been tested.

Frequently Asked Questions

What natural compounds protect against drug-induced liver injury?

N-acetyl cysteine (NAC) has the strongest clinical evidence and is used as a pharmaceutical antidote for acetaminophen overdose. Milk thistle (silymarin) has preclinical and some clinical support. Ergothioneine, a mushroom-derived thiol antioxidant, has shown consistent hepatoprotection in preclinical models of liver injury, including CCl4-induced toxicity and fibrosis (Mao 2025) and ischemia-reperfusion injury (Bedirli 2004). Human DILI trials for ergothioneine do not exist, so it should not be considered a treatment. Suspected liver injury requires medical evaluation, not a supplement.

How does ergothioneine protect against DILI?

In animal models, researchers have proposed at least four mechanisms: scavenging reactive oxygen species produced during drug metabolism via its thiol group; inhibiting the lipid peroxidation chain reactions that spread membrane damage; engaging the Nrf2 pathway, which drives cellular production of glutathione and other antioxidant enzymes; and inducing HSP70, a stress protein that helps liver cells survive acute toxic insults (Bedirli 2004). Mao et al. (2025) additionally identified PLA2G2A inhibition and TGF-beta/Smads pathway blockade. These mechanisms are established in rodents and cells, not demonstrated in humans.

What is the mechanism of drug-induced liver toxicity?

Most DILI involves reactive metabolites generated during drug processing by cytochrome P450 enzymes. These metabolites deplete glutathione, generate reactive oxygen species, cause lipid peroxidation, impair mitochondria, and trigger hepatocyte death. Inflammation amplifies the initial damage. The severity depends on the ratio of reactive metabolite generation to the liver's remaining antioxidant capacity.

Can antioxidants prevent drug-induced liver damage?

In preclinical models, yes: antioxidants including ergothioneine, NAC, and vitamin E have all shown hepatoprotective effects in animal DILI models. Whether this translates clinically depends on timing, dose, and the specific DILI mechanism involved, and for most antioxidants it has not been shown to translate. NAC is the exception, clinically established for acetaminophen specifically. Ergothioneine's theoretical advantage is that it accumulates in stressed tissue and engages Nrf2, which would help rebuild depleted antioxidant defenses rather than only neutralizing individual reactive species — but that advantage remains theoretical, as no human trial has tested it.

Does ergothioneine protect against hepatotoxic drugs?

In animals, ergothioneine has reduced liver injury markers in several relevant models: CCl4 chemical hepatotoxicity and fibrosis (Mao 2025) and ischemia-reperfusion liver injury (Bedirli 2004). A 1983 pair of papers examined its effects on the hepatic drug-metabolizing enzyme system, though no abstracts are indexed for them. No human trial has tested ergothioneine in a DILI context, and no case reports exist. The evidence is mechanistically consistent but entirely preclinical, so the accurate answer is that it protects rodent livers in laboratory models and has never been shown to protect a human liver from a hepatotoxic drug.

Sources & References

1. 1RTHM-00009·Kawano, H et al. (1983). “Studies on ergothioneine. X. Effects of ergothioneine on the hepatic drug metabolizing enzyme system and on experimental hepatic injury in rats..” Chemical & pharmaceutical bulletin.Study breakdown →PubMed →↩
2. 2RTHM-00010·Kawano, H et al. (1983). “Studies on ergothioneine. XI. Inhibitory effect on lipid peroxide formation in mouse liver..” Chemical & pharmaceutical bulletin.Study breakdown →PubMed →↩
3. 3RTHM-02138·Mao, Yaping et al. (2025). “Ergothioneine Ameliorates Liver Fibrosis by Inhibiting Glycerophospholipids Metabolism and TGF-β/Smads Signaling Pathway: Based on Metabonomics and Network Pharmacology..” Journal of applied toxicology : JAT.Study breakdown →PubMed →↩
4. 4RTHM-00128·Bedirli, Abdulkadir et al. (2004). “Ergothioneine pretreatment protects the liver from ischemia-reperfusion injury caused by increasing hepatic heat shock protein 70..” The Journal of surgical research.Study breakdown →PubMed →↩
5. 5RTHM-01517·Fu, Tong-Tong et al. (2022). “Ergothioneine as a Natural Antioxidant Against Oxidative Stress-Related Diseases..” Frontiers in pharmacology.Study breakdown →PubMed →↩
6. 6RTHM-00678·Cheah, Irwin K et al. (2021). “Ergothioneine, recent developments..” Redox biology.Study breakdown →PubMed →↩
7. 7RTHM-00696·Lam-Sidun, Daniel et al. (2021). “Mushroom-Derived Medicine? Preclinical Studies Suggest Potential Benefits of Ergothioneine for Cardiometabolic Health..” International journal of molecular sciences.Study breakdown →PubMed →↩
8. 8RTHM-00771·Cheah, Irwin K et al. (2016). “Liver ergothioneine accumulation in a guinea pig model of non-alcoholic fatty liver disease. A possible mechanism of defence?.” Free radical research.Study breakdown →PubMed →↩
9. 9RTHM-00856·Cheah, Irwin K et al. (2017). “Administration of Pure Ergothioneine to Healthy Human Subjects: Uptake, Metabolism, and Effects on Biomarkers of Oxidative Damage and Inflammation..” Antioxidants & redox signaling.Study breakdown →PubMed →↩
10. 10RTHM-01342·Dare, Ayobami et al. (2021). “L-ergothioneine and metformin alleviates liver injury in experimental type-2 diabetic rats via reduction of oxidative stress, inflammation, and hypertriglyceridemia..” Canadian journal of physiology and pharmacology.Study breakdown →PubMed →↩